PAVmed Inc.
Close on Oct 19, 2026
- Market cap
- $14.11M
- P/E (TTM)
- –
- Dividend yield
- –
About PAVmed
Surgical & Medical Instruments & Apparatus, SIC 3841
PAVmed Inc. is a diversified commercial-stage life sciences company operating across medical devices, diagnostics, and digital health through a shared services structure. Its diagnostics subsidiary, Lucid Diagnostics, provides the EsoCheck cell collection device and EsoGuard DNA test to detect esophageal precancer in at-risk patients with gastroesophageal reflux disease. Its digital health unit, Veris Health, delivers the Veris Cancer Care Platform and VerisBox connected devices for continuous physiological monitoring and remote symptom reporting during cancer treatment. In addition, the company develops medical devices, including the PortIO implantable intraosseous vascular access device and licensed endoscopic imaging technology. Customers and distribution channels include gastrointestinal specialists, primary care doctors, health systems, self-insured employers, unions, and cancer centers.
The company operates physical Lucid Test Centers in major metropolitan areas, uses satellite testing sites in physician clinics, and serves VA hospitals nationwide. It maintains an order fulfillment and packaging facility in Foxborough, Massachusetts, alongside a clinical laboratory in Lake Forest, California. The text does not disclose the location of its corporate headquarters.
Summary of the business section of PAVmed's latest annual report, written by StockData.
Company profile
Company
- Legal name
- PAVmed Inc.
- Headquarters
- New York, NY
- Address
- 360 Madison Avenue, 25th Floor 10017
- Phone
- (212) 949-4319
- Employees
- 3, Dec 31, 2016
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Marcum LLP, New York, NY
Stock & identifiers
- Ticker
- PAVM
- Exchange
- Nasdaq
- IPO date
- Jan 29, 2016
- Shares outstanding
- 8M, Aug 13, 2026
- Public float
- $11.80M, Jun 30, 2024
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-30 reverse, Mar 27, 2026; 1-for-30 reverse, Jan 2, 2026; 1-for-15 reverse, Mar 25, 2024; 1-for-15 reverse, Dec 7, 2023
- SEC CIK
- 1624326
- CUSIP
- 70387R502
- ISIN
- US70387R5028
- LEI
- 549300V1JXXVXU7P8007
- EIN
- 47-1214177
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Lishan Aklog | Chairman and CEO, Director | 367,573 |
| Victoria Tou-ho Lee | Chief Medical Officer | 1,666 |
| Dennis M. McGrath | President and CFO | 196,195 |
| Shaun O'Neil | Chief Operating Officer | 115,598 |
| Michael Adam Gordon | General Counsel | 115,000 |
| Michael J. Glennon | Director | 21,653 |
| Debra White | Director | 21,097 |
| Timothy E. Baxter | Director | 21,097 |
| Ronald M. Sparks | Director | 21,097 |
| Sundeep Agrawal | Director | 19,337 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Lishan Aklog, M.D | $1.03M | $992.47K | $595.77K | $3 | – |
| FY2025 Peo | $1.03M | $992.47K | $595.77K | $3 | – |
| FY2024 Lishan Aklog, M.D | $1.37M | $798.31K | $1.09M | $2 | – |
| FY2024 Peo | $1.37M | $798.31K | $1.09M | $2 | – |
| FY2023 Lishan Aklog, M.D | $953.20K | $882.53K | $627.33K | $11 | – |
| FY2023 Peo | $953.20K | $882.53K | $627.33K | $11 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“We have three employees and four executive officers, two of whom are also members of our Board of Directors.”
Corporate history
Events identified from SEC filings